Type
|
Public |
---|---|
Traded as |
|
Industry | Healthcare Diagnostic Substances |
Founded | 1983 (1983) |
Headquarters | Westbrook, Maine, United States |
Key people
|
|
Revenue | $ 1.77B (as of 31 December 2016) |
Number of employees
|
7,000 (as of 31 December 2016) |
Website | Idexx.com |
IDEXX Laboratories, Inc. (NASDAQ: IDXX) is an American multinational corporation on the S&P 500 and NASDAQ-100 indices engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 and headquartered in Westbrook, Maine, and EMEA in Hoofddorp, Netherlands, IDEXX offers products to customers in over 175 countries around the world and employs approximately 7,000 people in full-and part-time positions (as of 31 December 2016). There are three main segments of the company: Companion Animal Group, Water, and Livestock, Poultry and Dairy (LPD). In addition, the company also manufactures and sells pet-side SNAP tests for a variety of animal health diagnostic uses.
The Companion Animal Group ("CAG") provides in-clinic laboratory analyzers for companion animals. Analyzers measure blood cell counts as well as levels of certain enzymes in blood or urine for the purpose of monitoring health conditions. Major products of this segment are the Catalyst Dx Chemistry Analyzer and the VetTest Chemistry Analyzer, Symmetric dimethylarginine (SDMA), ProCyte Dx Hematology Analyzer, the LaserCyte Hematology Analyzer, the IDEXX VetAutoread Hematology Analyzer, the SNAP Pro analyzer, and so on, among other laboratory equipment and analytical services. Other areas of the CAG division are centered on diagnostic imaging and veterinary practice management software systems, including the flagship program Cornerstone, as well as DVMax (acquired from Sneakers Software, Inc., a New York City-based company, under terms of Ch. 11 reorganization [1]) in late 2012 [2]) and several legacy practice management software systems.
The Water segment provides products to measure microbiological parameters in water. Products of this segment include the Colilert, Colilert-18, and Colisure tests. Water products are sold in over 120 countries around the globe.
The Livestock and Poultry Diagnostics division provides products to detect diseases in livestock and poultry. Products of this segment include tests for Avian Infuenza (AI), Bovine Viral Diarrhea Virus (BVDV), Porcine Reproductive and Respiratory Syndrome (PRRS), and Bovine Spongiform Encephalopathy (BSE or mad cow disease).
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q4 2022 | 2023-02-06 | Future report Set alerts | |
Q3 2022 | 2022-11-01 | 2.15 | 2.15 |
Q2 2022 | 2022-08-02 | 1.56 | 1.56 |
Q1 2022 | 2022-05-04 | 2.27 | 2.27 |
Q4 2021 | 2022-02-02 | 1.89 | 1.89 |
Q3 2021 | 2021-11-02 | 2.03 | 2.03 |
Q2 2021 | 2021-07-30 | 2.34 | 2.34 |
Q1 2021 | 2021-05-04 | 2.35 | 2.35 |
Q4 2020 | 2021-02-02 | 2.01 | 2.01 |
Q3 2020 | 2020-10-29 | 1.69 | 1.69 |
2016-04-19 | Reiterated Rating | Canaccord Genuity | Buy | $80.00 to $85.00 |
2016-04-13 | Boost Price Target | Credit Suisse | Outperform | $80.00 to $85.00 |
2016-04-13 | Boost Price Target | Credit Suisse Group AG | Outperform | $80.00 to $85.00 |
2016-04-01 | Initiated Coverage | CL King | Neutral | |
2016-03-21 | Boost Price Target | Stifel Nicolaus | Buy | $80.00 to $85.00 |
2016-02-03 | Initiated Coverage | Credit Suisse | Outperform | $80.00 |
2016-02-01 | Reiterated Rating | Piper Jaffray | Neutral | $73.00 to $75.00 |
2016-02-01 | Reiterated Rating | Canaccord Genuity | Buy | $80.00 |
2016-02-01 | Reiterated Rating | Piper Jaffray Cos. | Neutral | $73.00 to $75.00 |
2016-01-31 | Reiterated Rating | William Blair | Outperform | |
2016-01-22 | Reiterated Rating | Canaccord Genuity | Buy | $80.00 |
2015-10-30 | Reiterated Rating | Canaccord Genuity | Buy | $80.00 |
2015-10-29 | Lower Price Target | Stifel Nicolaus | Buy | $85.00 to $80.00 |
2015-10-18 | Reiterated Rating | Canaccord Genuity | Buy | $87.00 |
2015-08-28 | Downgrade | Raymond James | Outperform to Market Perform | |
2015-08-28 | Downgrade | Raymond James Financial Inc. | Outperform to Market Perform | |
2015-08-13 | Boost Price Target | Stifel Nicolaus | Buy | $78.00 to $85.00 |
2015-08-10 | Boost Price Target | Piper Jaffray | Neutral | $70.00 to $77.00 |
2015-07-23 | Lower Price Target | Canaccord Genuity | Buy | $80.00 to $75.00 |
2015-07-23 | Upgrade | Feltl & Co. | Sell to Hold | $61.50 to $69.50 |
2015-06-29 | Reiterated Rating | Canaccord Genuity | Buy | $80.00 |
2015-05-28 | Reiterated Rating | Bank of America | Buy | $168.00 |
2015-05-28 | Reiterated Rating | Bank of America Corp. | Buy | $168.00 |
2015-04-29 | Lower Price Target | Stifel Nicolaus | Buy | $178.00 to $155.00 |
2015-04-28 | Lower Price Target | Canaccord Genuity | Buy | $175.00 to $160.00 |
2015-04-17 | Set Price Target | Stifel Nicolaus | Buy | $178.00 |
2015-02-15 | Reiterated Rating | Canaccord Genuity | Buy | $175.00 |
2015-02-02 | Reiterated Rating | Piper Jaffray | In-Line to Neutral | $160.00 |
2015-01-22 | Reiterated Rating | Canaccord Genuity | Buy | $160.00 to $175.00 |
2015-01-16 | Boost Price Target | Stifel Nicolaus | Buy | $155.00 to $178.00 |
2014-12-10 | Boost Price Target | Canaccord Genuity | Buy | $153.00 to $160.00 |
2014-10-28 | Boost Price Target | Canaccord Genuity | Buy | $139.00 to $153.00 |
2014-10-27 | Boost Price Target | Stifel Nicolaus | Buy | $135.00 to $155.00 |
2014-09-15 | Lower Price Target | Canaccord Genuity | Buy | $148.00 to $139.00 |
2014-08-20 | Downgrade | Northcoast Research | Neutral to Sell | |
2014-07-28 | Boost Price Target | Piper Jaffray | $125.00 to $126.00 | |
2014-06-24 | Upgrade | Canaccord Genuity | Hold to Buy | $116.00 to $148.00 |
2014-04-28 | Boost Price Target | Raymond James | Outperform | $123.00 to $135.00 |
2014-04-14 | Boost Price Target | Stifel Nicolaus | Buy | $120.00 to $135.00 |
2014-03-10 | Initiated Coverage | Piper Jaffray | Neutral | $121.00 to $125.00 |
2014-02-05 | Boost Price Target | Canaccord Genuity | $99.00 to $116.00 | |
2014-01-30 | Downgrade | Feltl & Co. | Hold to Sell | |
2013-11-14 | Reiterated | Stifel | Buy | $110 to $120 |
2013-11-14 | Boost Price Target | Stifel Nicolaus | Buy | $110.00 to $120.00 |
2013-07-15 | Upgrade | Stifel | Hold to Buy | $110 |
2012-03-15 | Initiated | Feltl & Co. | Hold | $87.50 |
2010-05-20 | Reiterated | Kaufman Bros | Buy | $77 to $75 |
2010-04-27 | Reiterated | Kaufman Bros | Buy | $70 to $77 |
2010-04-07 | Initiated | Kaufman Bros | Buy | $70 |
2010-02-01 | Downgrade | Avondale | Mkt Perform to Mkt Underperform | $42 |
2009-06-15 | Downgrade | Avondale | Mkt Outperform to Mkt Perform | |
2008-10-15 | Initiated | Avondale | Mkt Outperform | $55 |
2008-09-26 | Initiated | Sun Trust Rbsn Humphrey | Neutral | |
2007-12-14 | Initiated | JP Morgan | Overweight | |
2007-08-24 | Reiterated | CL King | Strong Buy | $105 to $125 |
2016-04-19 | Reiterated Rating | Canaccord Genuity | Buy | $80.00 to $85.00 |
2016-04-13 | Boost Price Target | Credit Suisse | Outperform | $80.00 to $85.00 |
2016-04-13 | Boost Price Target | Credit Suisse Group AG | Outperform | $80.00 to $85.00 |
2016-04-01 | Initiated Coverage | CL King | Neutral | |
2016-03-21 | Boost Price Target | Stifel Nicolaus | Buy | $80.00 to $85.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In IDXX 624 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Inc. | 8.79M |
Vanguard Group, Inc | 8.05M |
STATE STREET CORP | 3.78M |
BlackRock Fund Advisors | 3.71M |
Fundsmith LLP | 3.62M |
BlackRock Institutional Trust Company, N.A. | 3.26M |
ALLIANCEBERNSTEIN L.P. | 2.91M |
BAMCO INC /NY/ | 2.39M |
GEODE CAPITAL MANAGEMENT, LLC | 1.89M |
FMR LLC | 1.60M |
AMERICAN CENTURY COMPANIES INC | 1.53M |
BROWN ADVISORY INC | 1.21M |
FRANKLIN RESOURCES INC | 1.21M |
PRINCIPAL FINANCIAL GROUP INC | 1.20M |
Select Equity Group, L.P. | 1.08M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
AYERS JONATHAN W Chairman, President & CEO | 2.12% (1063398) | IDXX / |
Williams Michael J PhD Executive Vice President | 0.12% (59113) | IDXX / |
MCKEON BRIAN P | 0.09% (44040) | ATHN / IDXX / |
END WILLIAM T | 0.08% (41256) | IDXX / |
MURRAY ROBERT J | 0.07% (36347) | IDXX / LOJN / THG / TUP / |
RAINES MERILEE Executive VP & CFO | 0.05% (26577) | AFFX / IDXX / PETX / WTS / |
POWERS JOHNNY D Executive Vice President | 0.05% (25961) | IDXX / |
CRAIG THOMAS | 0.05% (24471) | IDXX / |
MAZELSKY JAY Executive Vice President | 0.04% (20760) | IDXX / |
HENDERSON REBECCA M | 0.04% (19852) | AMGN / IDXX / |
NAQUI ALI Corporate Vice President | 0.03% (17513) | IDXX / |
BROWN WILLIAM E III Executive Vice President | 0.03% (17259) | IDXX / |
TWIGGE GIOVANI CORPORATE VICE PRESIDENT | 0.03% (15738) | IDXX / |
POLEWACZYK JAMES F Corporate Vice President | 0.01% (6955) | IDXX / |
Vandebroek Sophie V. | 0.01% (6096) | ALOG / IDXX / |
Studer Jacqueline CVP, Gen. Counsel & Secretary | 0.01% (5077) | IDXX / MDRX / |
Kingsley Lawrence D | 0.01% (4654) | IDXX / IEX / PII / PLL / ROK / |
Meyaard Daniel V Corporate Vice President | 0.01% (4416) | IDXX / |
JOHNSON BARRY C | 0.01% (3560) | CYT / IDXX / ROK / |
JUNIUS DANIEL M | 0.01% (2659) | GLYC / IDXX / IMGN / VTAE / |